Depolymerizing self-immolative polymeric lanthanide chelates for vascular imaging
Source abstract
Abstract
Medical imaging is widely used clinically and in research to understand disease progression and monitor responses to therapies. Vascular imaging enables the study of vascular disease and therapy, but exogenous contrast agents are generally needed to distinguish the vasculature from surrounding soft tissues. Lanthanide-based agents are commonly employed in MRI, but are also of growing interest for micro-CT, as the position of their k-edges allows them to provide enhanced contrast and also to be employed in dual-energy micro-CT, a technique that can distinguish contrast-enhanced blood vessels from tissues such as bone. Small molecule Gd3+ chelates are available, but are excreted too rapidly. At the same time, a lack of rapid clearance from the body for long-circulating agents presents toxicity concerns. To address these challenges, we describe here the use of self-immolative polymers for the development of new degradable chelates that depolymerize completely from end-to-end following the cleavage of a single end-cap from the polymer terminus. We demonstrate that tuning the end-cap allows the rate of depolymerization to be controlled, while tuning the polymer length enables the polymer to exhibit long circulation times in the blood of mice. After successfully providing one hour of blood contrast, depolymerization led to excretion of the resulting small molecule chelates into the bladder. Despite the high doses required for micro-CT, the agents were well tolerated in mice. Thus, these self-immolative polymeric chelates provide a new platform for the development of medical imaging contrast agents. STATEMENT OF SIGNIFICANCE: Vascular imaging is used clinically to diagnose and monitor vascular disease and in research to understand the progression of disease and study responses to new therapies. For techniques such as magnetic resonance imaging and x-ray computed tomography (CT), long circulating contrast agents are needed to differentiate the vasculature from surrounding tissues. However, if these agents are not rapidly excreted from the body, they can lead to toxicity. We present here a new polymeric system that can chelate hundreds of lanthanide ions for imaging contrast and can circulate for one hour in the blood, but then after end-cap cleavage breaks down completely into small molecules for excretion. The successful application of this system in micro-CT in mice is demonstrated.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Lanthanide and Transition Metal Complexes · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (62)
Show source-provided references
1. PET imaging of a collagen matrix reveals its effective injection and targeted retention in a mouse model of myocardial infarction10.1016/j.biomaterials.2015.01.016 ↗
2. Preclinical applications of multi-platform imaging in animal models of cancer10.1158/0008-5472.CAN-20-0373 ↗
3. Magnetic resonance imaging of the atherosclerotic mouse aorta10.1007/978-1-4939-2929-0_29 ↗
4. In vivo small-animal imaging using micro-CT and digital subtraction angiography10.1088/0031-9155/53/19/R01 ↗
5. Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells10.1038/nbt.1845 ↗
6. Anatomical and functional imaging of myocardial infarction in mice using micro-ct and eXIA 160 contrast agent10.1002/cmmi.1557 ↗
7. X-ray-computed tomography contrast agents10.1021/cr200358s ↗
8. Chemistry of MRI contrast agents: current challenges and new frontiers
9. Time-course of contrast enhancement in spleen and liver with eXIA 160, Fenestra LC, and VC10.1007/s11307-008-0186-8 ↗
10. Biodegradable iodinated polydisulfides as contrast agents for CT agiography10.1016/j.biomaterials.2014.03.054 ↗
11. Computed tomography imaging of macrophage phagocytic activity in abdominal aortic aneurysm10.7150/thno.55106 ↗
12. Nanopolymersomes with an ultrahigh iodine content for high-performance x-ray computed tomography imaging in vivo10.1002/adma.201603997 ↗
13. Gold nanoparticles allow detection of early-stage edema in mice via computed tomography imaging10.2147/IJN.S77383 ↗
14. Tantalum oxide nanoparticles as versatile contrast agents for x-ray computed tomography10.1039/D0NR01234C ↗
15. Optimization of Bi3+ in upconversion nanoparticles induced simultaneous enhancement of near-infrared optical and x-ray computed tomography imaging capability10.1021/acsami.6b08335 ↗
16. Radioprotective garment-inspired biodegradable polymetal nanoparticles for enhanced CT contrast production10.1021/acs.chemmater.9b03931 ↗
17. Nanoparticles contrast agents for x-ray imaging applications10.1002/wnan.1642 ↗
18. Small is smarter: nano MRI contrast agents - advantages and recent achievements10.1002/smll.201502309 ↗
19. K shell parameters of some lanthanide elements using bremsstrahlung10.1016/j.radphyschem.2014.09.013 ↗
20. Experimental and theoretical x-ray imaging performance comparison of iodine and lanthanide contrast agents10.1118/1.597134 ↗
21. Dual-energy computed tomography using a gantry-based preclinical cone-beam microcomputed tomography scanner10.1117/1.JMI.5.3.033503 ↗
22. Polymer assembly encapsulated lanthanide nanoparticles as contrast agents for in vivo micro-CT10.1021/acs.biomac.7b01685 ↗
23. PEG-modified gadolinium nanoparticles as contrast agents for in vivo micro-CT10.1038/s41598-021-95716-x ↗
24. A high performance ytterbium-based nanoparticulate contrast agent for in vivo x-ray computed tomography imaging10.1002/anie.201106686 ↗
25. Biodegradable polysulfide dendrimer nanoclusters as mri contrast agents10.1021/nn304160p ↗
26. Facile synthesis and in vivo evaluation of biodegradable dendritic MRI contrast agents10.1039/c2jm32211k ↗
27. Synthesis and characterization of poly(L-glutamic acid) gadolinium chelate: a new biodegradable MRI contrast agent10.1021/bc049910m ↗
28. Pharmacokinetics and magnetic resonance imaging of biodegradable macromolecular blood-pool contrast agent pggd in non-human primates: a pilot study10.1002/cmmi.431 ↗
29. Poly(l-glutamic acid) Gd(III)-DOTA conjugate with a degradable spacer for magnetic resonance imaging10.1021/bc0340464 ↗
30. Contrast-enhanced MRI with new biodegradable macromolecular Gd(III) complexes in tumor-bearing mice10.1002/mrm.20402 ↗
31. A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent10.1002/cmmi.1655 ↗
32. Triggering depolymerization: progress and opportunities for self-immolative polymers10.1021/acs.macromol.9b00965 ↗
33. Dendritic, oligomeric, and polymeric self-immolative molecular amplification10.1021/acs.chemrev.5b00372 ↗
34. The architectural evolution of self-immolative polymers10.1016/j.polymer.2020.122638 ↗
35. Self-immolative polymers10.1021/ja801065d ↗
36. Activity-linked labeling of enzymes by self-immolative polymers10.1021/bc9002037 ↗
37. Photocontrolled degradation of stimuli-responsive poly(ethyl glyoxylate): differentiating features and traceless ambient depolymerization10.1021/acs.macromol.6b01620 ↗
38. Single UV or near IR triggering event leads to polymer degradation into small molecules10.1021/mz3002403 ↗
39. Thermo-responsive self-immolative nanoassemblies: direct and indirect triggering10.1039/C7CC06410A ↗
40. Programmable microcapsules from self-immolative polymers10.1021/ja104812p ↗
41. Triggered transience of metastable poly(phthalaldehyde) for transient electronics10.1002/adma.201403045 ↗
42. End-capping strategies for triggering the end-to-end depolymerization of polyglyoxylates10.1021/acs.macromol.6b02320 ↗
43. Phase-switching depolymerizable poly(carbamate) oligomers for signal amplification in quantitative time-based assays10.1021/ma4007413 ↗
44. Self-immolative polymersomes for high-efficiency triggered release and programmed enzymatic reactions10.1021/ja5030832 ↗
45. Polyglyoxylamides: tuning structure and properties of self-immolative polymers10.1021/acs.macromol.8b02616 ↗
46. Controlled polymerization of ethyl glyoxylate using alkyllithium and alkoxide initiators10.1021/acs.macromol.8b01007 ↗
47. How to determine free Gd and free ligand in solution of Gd chelates. A technical note10.1002/cmmi.110 ↗
48. Evaluation of eXIA 160 cardiac-related enhancement in C57Bl/6 and BALB/c mice using micro-CT10.1002/cmmi.488 ↗
49. Longitudinal follow-up of cardiac structure and functional changes in an infarct mouse model using retrospectively gated micro-computed tomography10.1097/RLI.0b013e3181727519 ↗
50. Thermo-responsive self-immolative polyglyoxylamides10.1021/acs.biomac.0c00899 ↗
51. Greene · 1999
52. Polyglyoxylamides with a pH-mediated solubility and depolymerization switch10.1021/acs.macromol.1c01796 ↗
53. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture10.1021/ar900035f ↗
54. Metal-chelating polymers by anionic ring-opening polymerization and their use in quantitative mass cytometry10.1021/bm300613x ↗
55. An nmr protonation study of metal diethylenetriaminepentaacetic acid complexes10.1021/ed056p348 ↗
56. Spectrometric and theoretical investigation of the structures of cu and pd/dtpa complexes10.1007/s11224-007-9192-8 ↗
57. Factors affecting the clearance and biodistribution of polymeric nanoparticles10.1021/mp800051m ↗
58. Gadolinium-based mri contrast agents induce mitochondrial toxicity and cell death in human neurons, and toxicity increases with reduced kinetic stability of the agent10.1097/RLI.0000000000000567 ↗
59. An overview of the clinical pharmacokinetics of x-ray contrast media10.2165/00003088-199732030-00002 ↗
60. Comparison of small animal ct contrast agents10.1002/cmmi.1689 ↗
61. Insight into the dynamics of lanthanide-DTPA complexes as revealed by oxygen-17 NMR10.1021/ic3010085 ↗
62. Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis10.1148/radiol.2017162740 ↗